RHYTHM PHARMACEUTICALS, INC.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

RYTM$113.94+1.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except share and per share data)

	December 31,2025	December 31,2024
Assets
Current assets:
Cash and cash equivalents	$54,301	$89,137
Short-term investments	334,648	231,428
Accounts receivable, net	26,081	18,512
Inventory	25,753	18,741
Prepaid expenses and other current assets	26,133	16,382
Total current assets	466,916	374,200
Property and equipment, net	1,104	632
Right-of-use asset	3,049	3,477
Intangible assets, net	5,319	6,174
Restricted cash	522	464
Other long-term assets	3,286	7,326
Total assets	$480,196	$392,273
Liabilities, Convertible Preferred Stock and Stockholders’ equity
Current liabilities:
Accounts payable	$13,947	$12,328
Accrued expenses and other current liabilities	83,855	62,658
Other current liability - LG Chem	—	37,704
Deferred revenue	194	1,286
Deferred royalty obligation, current	7,296	1,541
Lease liability	650	—
Total current liabilities	105,942	115,517
Long-term liabilities:
Deferred royalty obligation	100,886	108,269
Lease liability, non-current	3,342	3,938
Derivative liability	—	—
Total liabilities	210,170	227,724
Commitments and contingencies (Note 12)
Series A convertible preferred stock, $0.001 par value: 150,000 shares authorized; 132,500 and 150,000 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively. Liquidation preference of $132,500 and $150,000 as of December 31, 2025, and December 31, 2024, respectively.	130,957	142,820
Stockholders’ equity:
Common stock, $0.001 par value: 120,000,000 shares authorized; 67,205,321 and 62,390,654 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	67	61
Additional paid-in capital	1,491,675	1,177,045
Accumulated other comprehensive (loss) income	(796)	(39)
Accumulated deficit	(1,351,877)	(1,155,338)
Total stockholders’ equity	139,069	21,729
Total liabilities, convertible preferred stock and stockholders’ equity	$480,196	$392,273

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.